Published in J Exp Med on January 01, 1996
Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev (2009) 3.56
Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med (2011) 3.11
Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A (1997) 2.56
Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J (1999) 1.59
The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol (2009) 1.57
The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. J Autoimmun (2007) 1.55
CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. J Exp Med (1999) 1.39
The adenovirus E3/10.4K-14.5K proteins down-modulate the apoptosis receptor Fas/Apo-1 by inducing its internalization. Proc Natl Acad Sci U S A (1998) 1.36
CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol (2000) 1.35
Requirement of CD40-CD40 ligand interaction for elimination of Cryptosporidium parvum from mice. Infect Immun (1998) 1.27
Assembly and regulation of the CD40 receptor complex in human B cells. J Exp Med (1997) 1.17
Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J Exp Med (1997) 1.09
Involvement of FAN in TNF-induced apoptosis. J Clin Invest (2001) 1.08
Autoimmunity in hyper-IgM syndrome. J Clin Immunol (2008) 1.06
X-linked immunodeficiency with hyper-IgM (XHIM). Clin Exp Immunol (2000) 1.02
TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells. Mol Cell Biol (2005) 1.01
Primary and malignant cholangiocytes undergo CD40 mediated Fas dependent apoptosis, but are insensitive to direct activation with exogenous Fas ligand. PLoS One (2010) 0.99
Differential induction of nuclear factor-kappaB and activator protein-1 activity after CD40 ligation is associated with primary human hepatocyte apoptosis or intrahepatic endothelial cell proliferation. Mol Biol Cell (2003) 0.97
Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol (2006) 0.96
Mononuclear cell subpopulations in preterm and full-term neonates: independent effects of gestational age, neonatal infection, maternal pre-eclampsia, maternal betamethason therapy, and mode of delivery. Clin Exp Immunol (1999) 0.95
Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther (2007) 0.95
CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjögren's syndrome patients indicating their intrinsic activation. Clin Exp Immunol (2002) 0.92
RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1α release, and efficient paracrine dendritic cell activation. Oncotarget (2015) 0.91
CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Mol Pathol (2002) 0.88
The role of recipient T cells in mesenchymal stem cell-based tissue regeneration. Int J Biochem Cell Biol (2012) 0.86
The death domain kinase RIP1 links the immunoregulatory CD40 receptor to apoptotic signaling in carcinomas. J Cell Biol (2011) 0.85
Chronic immune activation in HIV-1 infection contributes to reduced interferon alpha production via enhanced CD40:CD40 ligand interaction. PLoS One (2012) 0.84
Marrow-derived CD40-positive cells are required for mice to clear Cryptosporidium parvum infection. Infect Immun (2001) 0.83
Levels of salivary IFN-gamma, TNF-alfa, and TNF receptor-2 as prognostic markers in (erosive) oral lichen planus. Mediators Inflamm (2011) 0.83
Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. Cancer Immunol Immunother (2014) 0.76
Unbalanced Immune System: Immunodeficiencies and Autoimmunity. Front Pediatr (2016) 0.75
A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis. Oncogene (2016) 0.75
CD40 mutant expression and its clinical significance to prognosis in gastric cancer patients. World J Surg Oncol (2014) 0.75
CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells. Cell Death Dis (2015) 0.75
Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models. Neuro Oncol (2016) 0.75
Apoptosis by CD95 (Fas)-dependent and -independent mechanisms in Peyer's patch lymphocytes in murine retrovirus-induced immunodeficiency syndrome. J Virol (1996) 0.75
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther (2016) 0.75
pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res (1990) 12.75
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell (1991) 10.96
FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell (1995) 9.81
The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell (1995) 8.80
Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science (1985) 7.99
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science (1994) 7.34
A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med (1989) 7.07
The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity (1994) 6.18
The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell (1995) 5.97
RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell (1995) 5.73
Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell (1990) 5.73
A novel domain within the 55 kd TNF receptor signals cell death. Cell (1993) 5.59
A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem (1995) 5.34
Mechanism of antigen-driven selection in germinal centres. Nature (1990) 5.26
CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science (1993) 5.04
Molecular and biological characterization of a murine ligand for CD40. Nature (1992) 4.83
THREE DEGREES OF GUANYLIC ACID--INOSINIC ACID PYROPHOSPHORYLASE DEFICIENCY IN MOUSE FIBROBLASTS. Nature (1964) 4.67
Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell (1990) 4.58
Mice deficient for the CD40 ligand. Immunity (1994) 4.45
Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature (1993) 4.39
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell (1993) 4.30
Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature (1995) 4.20
CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature (1993) 4.11
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A (1983) 3.83
A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem (1993) 3.81
Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci U S A (1991) 3.76
Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science (1995) 3.76
Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci U S A (1986) 3.68
Susceptibility of human diploid fibroblast strains to transformation by SV40 virus. Science (1966) 3.68
CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med (1990) 3.67
A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J (1989) 3.62
Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature (1991) 3.61
Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science (1988) 3.60
Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature (1995) 3.59
Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A (1990) 3.59
Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science (1991) 3.56
Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem (1992) 3.48
Negative selection of lymphocytes. Cell (1994) 3.47
How B and T cells talk to each other. Nature (1994) 3.37
A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem (1994) 3.13
FAP-1: a protein tyrosine phosphatase that associates with Fas. Science (1995) 3.06
Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med (1993) 3.04
Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J (1993) 2.98
The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem (1992) 2.90
CD40 is functionally expressed on human thymic epithelial cells. J Immunol (1992) 2.29
Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity (1994) 2.21
Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways. J Immunol (1994) 2.06
Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J (1994) 2.05
CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells. J Immunol (1991) 2.04
A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. FEBS Lett (1995) 1.97
Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes. Int J Cancer (1989) 1.76
Isolation and characterization of human tonsil dendritic cells. J Exp Med (1988) 1.74
Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J Immunol (1984) 1.64
Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol (1992) 1.62
Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2. J Exp Med (1994) 1.45
The role of tyrosine phosphorylation in signal transduction through surface Ig in human B cells. Inhibition of tyrosine phosphorylation prevents intracellular calcium release. J Immunol (1991) 1.36
Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem (1991) 1.31
A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother (1985) 1.29
Fas/Apo-1 activates nuclear factor kappa B and induces interleukin-6 production. J Inflamm (1995) 1.05
Rescue from anti-IgM-induced programmed cell death by the B cell surface proteins CD20 and CD40. Eur J Immunol (1992) 1.00
A cytotoxic CD40/p55 tumor necrosis factor receptor hybrid detects CD40 ligand on herpesvirus saimiri-transformed T cells. Eur J Immunol (1995) 0.82
CD40 function in nonhematopoietic cells. Nuclear factor kappa B mobilization and induction of IL-6 production. J Immunol (1995) 0.81
Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med (1992) 3.37
Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol (2001) 3.34
Soluble cytokine receptors are present in normal human urine. J Exp Med (1989) 2.24
Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol (1988) 2.02
Investigation of large intramolecular movement within metmyoglobin by Rayleigh scattering of Mössbauer radiation (RSMR). Z Naturforsch C (1982) 1.93
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum (1992) 1.74
Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res (2004) 1.66
Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J (1999) 1.59
TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. EMBO J (2001) 1.42
Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. EMBO J (1992) 1.39
Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res (1992) 1.33
Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine (1996) 1.33
Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (2002) 1.30
Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfectants. Eur J Immunol (1995) 1.28
Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum (1993) 1.22
Circulating plasma receptors for tumour necrosis factor in Malawian children with severe falciparum malaria. Cytokine (1993) 1.09
Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Immunol (1992) 1.05
Fas/Apo-1 activates nuclear factor kappa B and induces interleukin-6 production. J Inflamm (1995) 1.05
The myeloid differentiation antigen CD14 is N- and O-glycosylated. Contribution of N-linked glycosylation to different soluble CD14 isoforms. Eur J Biochem (1996) 1.04
Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J Exp Med (1994) 1.03
CD40 induces resistance to TNF-mediated apoptosis in a fibroblast cell line. Eur J Immunol (1998) 1.01
Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis (2000) 1.00
Soluble and cell surface receptors for tumor necrosis factor. Agents Actions Suppl (1991) 0.99
Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J Chromatogr (1990) 0.96
Monoclonal antibodies to the soluble human IL-6 receptor: affinity purification, ELISA, and inhibition of ligand binding. Hybridoma (1991) 0.95
Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta. Blood (1993) 0.89
GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing. Oncogene (2006) 0.87
The gene for the type II (p75) tumor necrosis factor receptor (TNF-RII) is localized on band 1p36.2-p36.3. Hum Genet (1991) 0.86
Cross-protection against homologous drift variants of influenza A and B after vaccination with split vaccine. Intervirology (2006) 0.86
The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases. Isr J Med Sci (1992) 0.85
Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies. Hybridoma (1997) 0.85
Influenza vaccination in liver transplant recipients. Transplantation (1999) 0.85
Cardiodepression by tumor necrosis factor-alpha. Eur Cytokine Netw (1998) 0.84
Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients. Clin Exp Immunol (1999) 0.83
Immune response to influenza vaccination. Lancet (1994) 0.83
Measurement of the postruminal digestibility of crude protein by the bag technique in cows. Arch Tierernahr (1985) 0.82
A cytotoxic CD40/p55 tumor necrosis factor receptor hybrid detects CD40 ligand on herpesvirus saimiri-transformed T cells. Eur J Immunol (1995) 0.82
Possible objectification of a critical maximum diameter for elective surgery in abdominal aortic aneurysms based on one- and three-dimensional ratios. J Cardiovasc Surg (Torino) (1997) 0.82
Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2. Br J Cancer (1992) 0.81
CD40 function in nonhematopoietic cells. Nuclear factor kappa B mobilization and induction of IL-6 production. J Immunol (1995) 0.81
Selective decrease in cell surface expression and mRNA level of the 55-kDa tumor necrosis factor receptor during differentiation of HL-60 cells into macrophage-like but not granulocyte-like cells. J Immunol (1992) 0.81
Replacement therapy for a homozygous protein C deficiency-state using a concentrate of human protein C and S. Br J Haematol (1988) 0.79
Soluble tumour necrosis factor receptors (sTNF-R) and HIV infection: correlation to CD8+ lymphocytes. Clin Exp Immunol (1993) 0.79
Functional discrepancies between tumor necrosis factor and lymphotoxin alpha explained by trimer stability and distinct receptor interactions. Eur J Immunol (1995) 0.79
Endothelial expression of CD40 in renal cell carcinoma. Cancer Res (1997) 0.79
Immunogenicity and safety of influenza vaccination in 3- to 6-year-old children with a two dose immunisation schedule. Eur J Pediatr (1996) 0.76
Sensitizing effects and mechanisms of desensitization in regulation of the in vivo response to TNF. Ann Inst Pasteur Immunol (1988) 0.75
Identification of two U937 cell sublines exhibiting different patterns of response to tumour necrosis factor. Cytokine (2001) 0.75
[Methodologic studies of ileal flow measurement using large lumen intestinal cannulae in swine]. Arch Tierernahr (1986) 0.75
[Effect of the content of plant crude protein in the ration on the utilization of urea by the milk cow. 1. Nitrogen digestibility and utilization of urea for bacterial protein synthesis in the rumen]. Arch Tierernahr (1983) 0.75